High-Dose-Rate Rotte "Y" Applicator Brachytherapy for Definitive Treatment of Medically Inoperable Endometrial Cancer: 10-Year Results

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 3, 2008, Pages 779-783

  Coon, Devin ^a   Beriwal, Sushil ^a   Heron, Dwight E ^a   Kelley, Joseph L ^a   Edwards, Robert P ^a   Sukumvanich, Paniti ^a   Zorn, Kristin K ^a   Krivak, Thomas C ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

HDR brachytherapy; Twice daily dosing; Uterine cancer

Indexed keywords

DOSIMETRY; PATIENT MONITORING; PATIENT TREATMENT; TOXICITY;

HDR BRACHYTHERAPY; TWICE-DAILY DOSING; UTERINE CANCER;

ONCOLOGY;

ADULT; AGED; ARTICLE; BODY MASS; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RADIATION APPLICATOR; RADIATION DOSE; RADIATION DOSE FRACTIONATION; ROTTE Y APPLICATOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DOSE FRACTIONATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; RADIATION INJURIES; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 44449098185     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.10.026     Document Type: Article

References (20)

1. American Cancer Society. Cancer facts and figures (2007), American Cancer Society, Atlanta, GA p. 4
2. Barakat R., Grigsby P.W., and Sabbatini P. In: Hoskins W.J. (Ed). Principles and practice of gynecologic oncology. 4th ed. (2005), Lippincott Williams & Wilkins, Philadelphia 961-981
3. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
4. Scholten A.N., van Putten W.L., Beerman H., et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63 (2005) 834-838
5. Rose P.G., Baker S., Kern M., et al. Primary radiation therapy for endometrial carcinoma: A case controlled study. Int J Radiat Oncol Biol Phys 27 (1993) 585-590
6. Rouanet P., Dubois J.B., Gely S., et al. Exclusive radiation therapy in endometrial carcinoma. Int J Radiat Oncol Biol Phys 26 (1993) 223-228
7. Rotte K., and Schneider J. Technique and results of HDR afterloading in cancer of the endometrium. In: Martinez A., Orton C., and Mould R. (Eds). Brachytherapy HDR and LDR (1990), Nucletron Corp., Columbia, MD 68-79
8. Nori D., Hilaris B., Anderson L., et al. A new endometrial applicator. Int J Radiat Oncol Biol Phys 8 (1982) 941-945
9. Bauer M., and Schulz-Wendtland R. A new afterloading applicator for primary brachytherapy of endometrial cancer. SELECTRON Brachyther J Suppl 2 (1991) 56-58
10. Gerszten K., Faul C., Kelley J., et al. Twice-daily high-dose-rate brachytherapy for medically inoperable uterine cancer. Brachytherapy 5 (2006) 118-121
11. U.S. Bureau of the Census. Current population reports, special studies, P23-190, 65+ in the United States (1996), U.S. Government Printing Office, Washington, DC
12. Modesitt S.C., and van Nagell Jr. J.R. The impact of obesity on the incidence and treatment of gynecologic cancers: A review. Obstet Gynecol Surv 60 (2005) 683-692
13. Knocke T.H., Kucera H., Weidinger B., et al. Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy: Results of 12 years of experience with 280 patients. Int J Radiat Oncol Biol Phys 37 (1997) 359-365
14. Kucera H., Knocke T.H., Kucera E., et al. Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstet Gynecol Scand 77 (1998) 1008-1012
15. Chao C.K., Grigsby P.W., Perez C.A., et al. Brachytherapy-related complications for medically inoperable stage I endometrial carcinoma. Int J Radiat Oncol Biol Phys 31 (1995) 37-42
16. Petereit D.G., Sarkaria J.N., and Chappell R.J. Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy. Int J Radiat Oncol Biol Phys 42 (1998) 1025-1031
17. Niazi T.M., Souhami L., Portelance L., et al. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys 63 (2005) 1108-1113
18. Nguyen T.V., and Petereit D.G. High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecol Oncol 71 (1998) 196-203
19. Beriwal S., Kim H., Heron D.E., et al. Comparison of 2D vs. 3D dosimetry for Rotte 'Y' applicator high dose rate brachytherapy for medically inoperable endometrial cancer. Technol Cancer Res Treat 5 (2006) 521-527
20. Nag S., Erickson B., Parikh S., et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 48 (2000) 779-790